Summary

Eligibility
for males ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
completion around

Description

Summary

This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this study are:

  • Androgen deprivation therapy (ADT) with a drug of your physician's choice. This may include leuprolide (Lupron), goserelin acetate (Zoladex), or degarelix (Firmagon).
  • Docetaxel
  • Nivolumab

Official Title

A Phase 2 Multicohort Study of Nivolumab in Combination with Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients with DNA Damage Repair Defects or Inflamed Tumors

Details

Keywords

Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma, Prostatic Neoplasms, Adenocarcinoma, Neoplasm Metastasis, Hypersensitivity, Docetaxel, Nivolumab, Leuprolide, Goserelin, Androgens, Androgen Deprivation Therapy, Biomarker Negative

Eligibility

Locations

  • University of California, San Diego
    La Jolla California 92093 United States
  • University of Wisconsin
    Madison Wisconsin 53706 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Xiao X. Wei, MD
ID
NCT04126070
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 60 study participants
Last Updated